Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 24, 2015 10:54 PM ET

Biotechnology

Company Overview of Exosome Diagnostics, Inc.

Company Overview

Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company develops exosome-based diagnostics technology platform that harvests comprehensive and dynamic molecular information contained within exosomes from various fresh or frozen biofluids to deliver personalized healthcare to guide treatment decisions and in real-time along the entire patient care continuum. Its technology combines RNA analysis with DNA and protein analysis to deliver comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated, and monitored. The company al...

Riverside Technology Center

840 Memorial Drive

Suite 3

Cambridge, MA 02139

United States

Founded in 2008

Phone:

617-588-0500

Fax:

617-588-0580

Key Executives for Exosome Diagnostics, Inc.

Chief Executive Officer and Director
Age: 55
Chief Financial Officer
Age: 43
Chief Science Officer and Founding Scientist
Chief Medical Officer
Vice President of Business Development
Compensation as of Fiscal Year 2014.

Exosome Diagnostics, Inc. Key Developments

Exosome Diagnostics, Inc. Announces Positive Results from Initial Clinical Study of Novel Prostate Cancer Liquid Biopsy

Exosome Diagnostics, Inc. announced positive data from an initial clinical study of the company's novel prostate cancer liquid biopsy. The non-invasive, RNA-based test demonstrated the potential to accurately predict high-grade prostate cancer by analyzing biomarkers on exosomal RNA (exoRNA) via a simple urine sample. The data were presented at a poster session titled, A first catch, non-DRE urine exosome gene signature to predict Gleason 7 prostate cancer on an initial prostate biopsy, at the 2015 Genitourinary Cancers Symposium taking place February 26-28, 2015 in Orlando, Florida.

Exosome Diagnostics, Inc. and Addario Lung Cancer Medical Institute Announce Collaboration to Accelerate Development of Plasma-Based Lung Cancer Diagnostics

Exosome Diagnostics, Inc. announced a strategic collaboration with the Addario Lung Cancer Medical Institute (ALCMI) to accelerate the development of its lead plasma-based diagnostics in development for mutation detection and monitoring in patients with lung cancer. The collaboration will support validation of Exosome Diagnostics ALK and T790M lab developed tests (LDTs) planned to launch in 2015 and help advance future development of the company’s ALK and T790M in vitro diagnostic (IVD) kits. Exosome Diagnostics ALK and T790M tests have the potential to provide clinicians with real-time, precise molecular insights to help inform individualized treatment decisions for patients with lung cancer upon initial diagnosis and throughout the course of treatment. Exosome Diagnostics novel technology platform enables the development of tests that can analyze stable, high-quality exosomal RNA (exoRNA), representing a potentially important advance given that many known cancer mutations, such as gene arrangements and splice variants, are difficult or impossible to detect utilizing circulating DNA analysis.

Exosome Diagnostics Appoints Thomas McLain as Chief Executive Officer, Effective July 23, 2014

Exosome Diagnostics announced the appointment of Thomas McLain as its chief executive officer, effective July 23, 2014. Mr. McLain most recently was the CEO of Vermillion.

Similar Private Companies By Industry

Company Name Region
One Cell Systems, Inc. United States
Kemp Biotechnologies Inc. United States
ChemoCore Therapeutics, Inc. United States
Dharmacon, Inc. United States
Aursos, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Exosome Diagnostics, Inc., please visit www.exosomedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.